Literature DB >> 9774244

Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV.

J Kilbride1, L Q Huang, M J Rowan, R Anwyl.   

Abstract

Electrophysiological studies were carried out on the presynaptic inhibitory action of the group II metabotropic glutamate (mGlu) receptor agonists (+)-2-aminobicyclo[3.1.0]hexane-2-6-dicarboxylic acid (LY354740) and (2S,1'R,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV) in three paths of the rat hippocampus, the medial and lateral perforant path to the dentate gyrus, and the Schaffer collateral/commissural path to CA1. LY354740 caused a dose-dependent reversible inhibition of the field excitatory postsynaptic potential (EPSP) in the medial and lateral perforant paths, with an EC50 of 115 +/- 16 nM and 230 +/- 58 nM, respectively. Maximal inhibition by LY354740 was much greater in the medial path (about 80%) than in the lateral path (about 50%). No inhibition was observed in CA1. A presynaptic inhibition was confirmed by LY354740 inducing dose-dependent changes in paired-pulse depression/facilitation. DCG-IV had a similar action to LY354740, but with a lower potency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774244     DOI: 10.1016/s0014-2999(98)00526-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Developmental regulation of hippocampal excitatory synaptic transmission by metabotropic glutamate receptors.

Authors:  F M Ross; J Cassidy; M Wilson; S N Davies
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

2.  Plasticity of NMDA receptor-mediated excitatory postsynaptic currents at perforant path inputs to dendrite-targeting interneurons.

Authors:  Sarah C Harney; Roger Anwyl
Journal:  J Physiol       Date:  2012-05-21       Impact factor: 5.182

3.  Glutamatergic modulation of auditory information processing in the human brain.

Authors:  Handan Gunduz-Bruce; Robert M G Reinhart; Brian J Roach; Ralitza Gueorguieva; Stephen Oliver; Deepak C D'Souza; Judith M Ford; John H Krystal; Daniel H Mathalon
Journal:  Biol Psychiatry       Date:  2011-10-29       Impact factor: 13.382

4.  cAMP-dependent protein kinase inhibits mGluR2 coupling to G-proteins by direct receptor phosphorylation.

Authors:  H Schaffhauser; Z Cai; F Hubalek; T A Macek; J Pohl; T J Murphy; P J Conn
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

5.  Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology.

Authors:  Jorge E Quintero; François Pomerleau; Peter Huettl; Kirk W Johnson; James Offord; Greg A Gerhardt
Journal:  Brain Res       Date:  2011-05-18       Impact factor: 3.252

6.  Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion.

Authors:  Alan L Pehrson; Bita Moghaddam
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

7.  Group II/III metabotropic glutamate receptors exert endogenous activity-dependent modulation of TRPV1 receptors on peripheral nociceptors.

Authors:  Susan M Carlton; Shengtai Zhou; Rosann Govea; Junhui Du
Journal:  J Neurosci       Date:  2011-09-07       Impact factor: 6.167

8.  Interhemispheric regulation of the medial prefrontal cortical glutamate stress response in rats.

Authors:  Derek Lupinsky; Luc Moquin; Alain Gratton
Journal:  J Neurosci       Date:  2010-06-02       Impact factor: 6.167

9.  Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus.

Authors:  James J Doherty; Sudar Alagarsamy; Kristopher J Bough; P Jeffrey Conn; Raymond Dingledine; David D Mott
Journal:  J Physiol       Date:  2004-10-28       Impact factor: 5.182

10.  Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine.

Authors:  David A Baker; Aric Madayag; Lars V Kristiansen; James H Meador-Woodruff; Vahram Haroutunian; Ilangovan Raju
Journal:  Neuropsychopharmacology       Date:  2007-08-29       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.